Loading
CP
CStone Pharmaceuticals - B Stock: price and insider trades · Hong Kong
1 insider bought €303k of shares over the last 90 days, the latest by Yang Jianxin, filed 22 Sept 2026.
Insider Decl.
192
Thresholds
n/a
Buy Volume
€7M
94 ops. · all time
Sell Volume
€26M
28 ops. · all time
Who traded when
BuySaleYang Jianxin28 buys10 sales
Hu Edward3 buys2 sales
Li Wei3 buys
Hitchner III Kenneth Walton1 buy1 sale
Since the insiders bought
- -16.8%Entry HK$5.65 · Close 22 Oct 2026 HK$4.70
- +3.1%Entry HK$4.56 · Close 22 Oct 2026 HK$4.70
- -0.6%Entry HK$4.73 · Close 22 Oct 2026 HK$4.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,211 of 26,286 companies
19.3
score / 100
Value22
Quality16
FCF yld-4.2%
Earn yld-5.6%
EV/EBITDA·
ROE-52%
Gross mgn19%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$5.08
Analyst consensus
4 analysts1.25/5
HK$9.92Target HK$14.52(+186%)HK$20.06
Income statement
RevenueHK$269.6M
Gross profitHK$51.2M19% margin
EBITDA-HK$366.7M-136% margin
Net income-HK$437M-98.6% margin
Valuation
PER (forward)145.1x
P/Book5.3x
Beta0.22
Balance sheet & cash
Market capHK$8.1B
Total debtHK$348.5M
Free Cash Flow-HK$327.7M
Debt / Equity28%
Profitability & ownership
ROE-52.1%
ROA-14.4%
% insiders19.9%
% institutions15.5%
Last declaration on 9 October 2026
Declarations192 total
20,833 sharesShareXHKGHKEX:DA20261008E00563
20,833 sharesShareXHKGHKEX:DA20261008E00565
63,000 sharesShareXHKGHKEX:DA20261008E00561
6,875 sharesShareXHKGHKEX:DA20261003E00068
291,500 shares@ HK$5.63420.020% mcap1.3% of flowShareXHKGHKEX:DA20260922E00364
Canonical exit: 21 Dec 2026 (T+90)
72,000 shares@ HK$5.4250.0048% mcap0.3% of flowShareXHKGHKEX:DA20260918E00291
Canonical exit: 17 Dec 2026 (T+90)
132,500 shares@ HK$5.23610.0086% mcap0.6% of flowShareXHKGHKEX:DA20260917E00425
Canonical exit: 16 Dec 2026 (T+90)
41,666 sharesShareXHKGHKEX:DA20260909E00497
41,666 sharesShareXHKGHKEX:DA20260909E00519
208,500 sharesShareXHKGHKEX:DA20260909E00496
63,000 sharesShareXHKGHKEX:DA20260707E00463
20,833 sharesShareXHKGHKEX:DA20260707E00459
20,833 sharesShareXHKGHKEX:DA20260707E00453
448,875 sharesShareXHKGHKEX:DA20260701E00108
331,000 shares@ HK$4.64230.018% mcap18.5% of flowShareXHKGHKEX:DA20260701E00109
Canonical exit: 28 Sept 2026 (T+90)
62,499 sharesShareXHKGHKEX:DA20260701E00105
62,499 sharesShareXHKGHKEX:DA20260701E00098
11,270,000 sharesShareXHKGHKEX:DA20260625E00306
Canonical exit: 21 Sept 2026 (T+90)
100,000 shares@ HK$4.560.0053% mcap40.7% of flowShareXHKGHKEX:DA20260616E00325
Canonical exit: 10 Sept 2026 (T+90)
56,500 shares@ HK$4.660.0031% mcap3.1% of flowShareXHKGHKEX:DA20260615E00264
Canonical exit: 10 Sept 2026 (T+90)
150,000 shares@ HK$4.65680.0082% mcap61.0% of flowShareXHKGHKEX:DA20260615E00266
Canonical exit: 10 Sept 2026 (T+90)
100,000 shares@ HK$4.440.0052% mcap39.6% of flowShareXHKGHKEX:DA20260612E00329
Canonical exit: 9 Sept 2026 (T+90)
200,000 shares@ HK$4.570.011% mcap10.9% of flowShareXHKGHKEX:DA20260612E00338
Canonical exit: 10 Sept 2026 (T+90)
100,000 shares@ HK$4.46970.0052% mcap39.0% of flowShareXHKGHKEX:DA20260612E00327
Canonical exit: 9 Sept 2026 (T+90)
50,000 shares@ HK$4.400.0026% mcap19.7% of flowShareXHKGHKEX:DA20260611E00338
Canonical exit: 8 Sept 2026 (T+90)
25 of 192 declarations
About CStone Pharmaceuticals - B
At CStone Pharmaceuticals - B, a health care company listed on the Hong Kong stock exchange and valued at HKD 8.1 billion, one director dominates the record: Yang Jianxin signs 121 of the 192 filings, 76 of them purchases and 15 sales. The filer's largest purchase is worth EUR 439,627 on September 16, 2022, and a sale of EUR 7,808,482 dates from September 11, 2025. The largest purchase on record, EUR 633,697, is by Hu Edward (Director) on December 4, 2025.
The heaviest sales go back to 2020: Jiang Frank Ningjun (Director) sold EUR 8,095,914 on January 17, 2020 then EUR 5,452,342 on November 23, 2020. In all, 28 sales, 25 with an amount, are worth EUR 26,148,982 (median EUR 138,237), against 94 purchases, 83 with an amount, worth EUR 6,533,340 (median EUR 46,746). Purchases are 77% of open-market trades.
Read moreShow less
From June 3 to June 30, 2026, 5 insiders bought. Across the full history, 22 purchase filings are classed as clustered. Insiders hold 19.9% of the capital. Annual volume goes from 5 in 2019 to 50 in 2025. Over twelve months: 57 filings, 27 purchases, 4 sales. The 81 purchases with a result have a 90-day median of 21.9%, with 68% positive (recorded past results, not a forecast).
